Hummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma

Hummingbird Bioscience enters a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001,a potentially best-in-class anti-HER3 mAb,in combination with cetuximab,an anti-EGFR mAb,in sqNSCLC

HMBD-001 used as monotherapy and in combination with cetuximab has been shown to effectively inhibit tumor growth across various preclinical squamous cell carcinoma models

SAN FRANCISCO,HOUSTON and SINGAPORE,May 15,2023 --Hummingbird Bioscience,a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases,today announced it has entered into a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001 in combination with cetuximab in squamous non-small cell lung carcinoma (sqNSCLC).

Under this collaboration,Hummingbird Bioscience will evaluate the safety,tolerability,and anti-tumor activity of its potentially best-in-class HER3-targeting antibody,HMBD-001,in combination with standard of care chemotherapy with or without Merck's cetuximab,anti-EGFR mAb,in patients with sqNSCLC in a Phase 1b clinical trial,to be initiated in the second half of 2023. Merck will supply cetuximab for the Hummingbird Bioscience-sponsored study and both parties will retain all commercial rights to their respective compounds.

"We are excited to collaborate with Merck to study a promising,new treatment regimen for sqNSCLC patients with significant unmet need. This is the first squamous disease setting of several for which HER3 plays a critical role in etiology and where HER targeted therapies could potentially deliver clinical benefit," said Jerome Boyd-Kirkup,Ph.D.,Chief Scientific Officer,Hummingbird Bioscience. "In addition to standard of care chemotherapy,the inhibition of HER3 or the concurrent inhibition of HER3 and EGFR has significant potential to improve outcomes in sqNSCLC patients refractory to front-line immunotherapies."

Hummingbird Bioscience recently presented strong scientific rationale and preclinical data for HMBD-001 used as monotherapy and in combination with cetuximab in various squamous cell carcinomas at the American Association for Cancer Research 2023 Meeting in April.

About Hummingbird Bioscience

Hummingbird Bioscience is a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology with wet lab drug discovery in a multi-disciplinary,collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection,enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. We are currently developing two clinical-stage assets: HMBD-001,a humanized anti-HER3 monoclonal antibody targeting a novel epitope on HER3,and HMBD-002,a humanized anti-VISTA IgG4 monoclonal antibody. Both programs are currently in Phase 1 studies. At Hummingbird Bioscience,our commitment to rigorous science,teamwork and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.

For more information,please visitwww.hummingbirdbioscience.com,and follow Hummingbird Bioscience onLinkedIn,Twitter,andYouTube.

About HMBD-001

HMBD-001 is a clinical-stage IgG1 antibody designed to target HER3. Discovered using Hummingbird Bioscience's proprietary Rational Antibody Discovery (RAD) platform,HMBD-001 is now in development for the treatment of multiple solid tumors. We believe HMBD-001 is the only anti-HER3 antibody in development that has the potential to fully block both ligand-dependent and -independent HER3 activation and oncogenic signaling,by targeting a key epitope located at the interface where HER3 forms heterodimers with HER2 or EGFR. In preclinical models evaluating HMBD-001,the company has observed superior affinity and more potent tumor growth inhibition compared to existing anti-HER3 antibodies. Near-term development plans for HMBD-001 focus on a few priority,high-value indications with strong scientific rationale and supporting preclinical data,which includes HER3-driven cancers.